Connecticut MPJE Practice Test 2026 – All-in-One Resource to Master the Exam!

The FDA determines that certain listed drugs are not safe or effective, which prohibits pharmacies from compounding them. This designation is often based on evidence showing that these drugs may pose significant risks to patients, either due to their inherent nature or because they have been associated with adverse effects that outweigh any potential benefits.

The FDA maintains a list of drugs that have been withdrawn or removed from the market due to safety concerns, a lack of efficacy, or issues related to manufacturing. When a drug is on this list, it signals to pharmacies that compounding these medications could lead to harm or ineffective treatment for patients.

The other choices do not accurately reflect the FDA's reasoning. For instance, the FDA does not primarily base its decisions on cost or the need for special licenses. Instead, the focus is tightly linked to the safety and efficacy profile of the drug in question.